Evidence map›Paper›PMID 30501635›Full record

ArticleJournal of neuroinflammation2018

Counteracting neuroinflammation in experimental Parkinson's disease favors recovery of function: effects of Er-NPCs administration.

Stephana Carelli, Toniella Giallongo, Zuzana Gombalova, Federica Rey, Maria Carlotta F Gorio, Massimiliano Mazza, Anna Maria Di Giulio

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Stephana CarelliLaboratory of Pharmacology, Department of Health Sciences, University of Milan, Polo H. San Paolo, via A di Rudinì 8, 20142, Milan, Italy. stephana.carelli@unimi.it.
Toniella GiallongoLaboratory of Pharmacology, Department of Health Sciences, University of Milan, Polo H. San Paolo, via A di Rudinì 8, 20142, Milan, Italy.
Zuzana GombalovaLaboratory of Pharmacology, Department of Health Sciences, University of Milan, Polo H. San Paolo, via A di Rudinì 8, 20142, Milan, Italy.
Federica ReyLaboratory of Pharmacology, Department of Health Sciences, University of Milan, Polo H. San Paolo, via A di Rudinì 8, 20142, Milan, Italy.
Maria Carlotta F GorioDepartment of Biomedical and Clinical Science L. Sacco, University of Milan, Milan, Italy.
Massimiliano MazzaIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, 47014, Meldola, FC, Italy.
Anna Maria Di GiulioLaboratory of Pharmacology, Department of Health Sciences, University of Milan, Polo H. San Paolo, via A di Rudinì 8, 20142, Milan, Italy. annamaria.digiulio@unimi.it.
University of Milan · ITFoundation Jewish Contemporary Documentation Center · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParkinson's disease (PD) is the second most common neurodegenerative disease, presenting with midbrain dopaminergic neurons degeneration. A number of studies suggest that microglial activation may have a role in PD. It has emerged that inflammation-derived oxidative stress and cytokine-dependent toxicity may contribute to nigrostriatal pathway degeneration and exacerbate the progression of the disease in patients with idiopathic PD. Cell therapies have long been considered a feasible regenerative approach to compensate for the loss of specific cell populations such as the one that occurs in PD. We recently demonstrated that erythropoietin-releasing neural precursors cells (Er-NPCs) administered to MPTP-intoxicated animals survive after transplantation in the recipient's damaged brain, differentiate, and rescue degenerating striatal dopaminergic neurons. Here, we aimed to investigate the potential anti-inflammatory actions of Er-NPCs infused in an MPTP experimental model of PD.

methodsThe degeneration of dopaminergic neurons was caused by MPTP administration in C57BL/6 male mice. 2.5 × 10

resultsEr-NPC administration promoted a rapid anti-inflammatory effect that was already evident 24 h after transplant with a decrease of pro-inflammatory and increase of anti-inflammatory cytokines mRNA expression levels. This effect was maintained until the end of the observational period, 2 weeks post-transplant. Here, we show that Er-NPCs transplant reduces macrophage infiltration, directly counteracting the M1-like pro-inflammatory response of murine-activated microglia, which corresponds to the decrease of CD68 and CD86 markers, and induces M2-like pro-regeneration traits, as indicated by the increase of CD206 and IL-10 expression. Moreover, we also show that this activity is mediated by Er-NPCs-derived erythropoietin (EPO) since the co-injection of cells with anti-EPO antibodies neutralizes the anti-inflammatory effect of the Er-NPCs treatment.

conclusionThis study shows the anti-inflammatory actions exerted by Er-NPCs, and we suggest that these cells may represent good candidates for cellular therapy to counteract neuroinflammation in neurodegenerative disorders.

Indexed as

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsCoculture TechniquesCorpus StriatumCytokinesDisease Models, AnimalDopamine Plasma Membrane Transport ProteinsEncephalitisErythropoietinGreen Fluorescent ProteinsMaleMiceMice, Inbred C57BLMuscle StrengthNeural Stem CellsParkinsonian Disorders1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineCytokinesDopamine Plasma Membrane Transport ProteinsErythropoietinGreen Fluorescent ProteinsTyrosine 3-MonooxygenaseAdult stem cellsErythropoietinNeural stem cells transplantationNeuroinflammationParkinson’s diseaseRegenerative medicine

Identifiers

PMID30501635
PMCPMC6271641
OpenAlexW2903539013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.